Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017
BOULDER, Colo., May 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2017 and hold a conference call to discuss those results on Wednesday, May 10, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
| Date: |
Wednesday, May 10, 2017 |
| Time: |
9:00 a.m. Eastern Time |
| Toll-Free: |
(844) 464-3927 |
| Toll: |
(765) 507-2598 |
| Pass Code: |
92608803 |
Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/hgm92o9w
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to seven drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology), tucatinib (partnered with Cascadian Therapeutics) and ipatasertib (partnered with Roche).
| CONTACT: |
Tricia Haugeto |
| Array BioPharma Inc. |
|
| (303) 386-1193 |
|
SOURCE Array BioPharma
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article